Trial Information

Summary: Dosing Flexibility Study in Patients With RA

A Phase IIIb Open-Label Run-in and Double-Blind, Placebo Controlled, Randomized Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-Dose Methotrexate in Patients With Active Rheumatoid Arthritis.

To assess efficacy of two dose regimens in combination with Methotrexate

Inclusion Criteria:

• Patients with established adult rheumatoid arthritis currently on Methotrexate for at least 3 months

Exclusion Criteria:

• All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment.
• Previous clinical trials participation and previous biological therapy that could interfere with the results of the present clinical trial.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:43:14 AM